EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Synergistic prognostic effect of the renin‐angiotensin‐aldosterone system and immune‐checkpoint inhibition in advanced lung cancer: The SPERICIL study

Safa Can Efil iD, Sema Nur Ozsan Celebi, Beste Ozturk, Burak Bilgin iD, Mutlu Hizal, Sebnem Yucel, Muhammed Bulent Akinci, Didem Sener Dede, Bulent Yalcin, Mehmet Ali Nahit Sendur iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70169 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Safa Can Efil und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey. Hauptthemen laut MEDLINE: Lung Neoplasms, Renin-Angiotensin System, Immune Checkpoint Inhibitors, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preclinical studies revealed that renin‐angiotensin‐aldosterone system inhibitors (RAASi) may exhibit synergistic effects with immune‐checkpoint inhibitors (ICIs). Although limited clinical data support this synergy, the findings in lung cancer remain inconsistent. This study investigated the synergistic prognostic effect of concomitant RAASi use in patients with advanced lung cancer treated with ICIs. In this retrospective observational study, patients with advanced lung cancer who received ICIs between July 2018 and August 2024 were analyzed. Patients were dichotomised according to RAASi use. The primary endpoint was overall survival (OS), and secondary endpoints included progression‐free survival (PFS) and tumor response parameters. Cox regression analyses were performed to identify variables associated with OS and PFS. A total of 286 patients were included, among whom 94 (33%) received concomitant RAASi. The baseline characteristics of the two groups were relatively comparable. The RAASi user group demonstrated a significantly longer median OS (17.47 months vs. 10.02 months, p = 0.001) and PFS (8.31 vs. 3.84 months, p = 0.008) compared to the RAASi non‐user group. Multivariate analysis demonstrated that concomitant RAASi use was an independent predictor for OS (HR: 0.58; 95% CI, 0.43–0.80, p = 0.001). Although concomitant RAASi use was not an independent predictor for PFS, a trend toward statistical significance was observed (HR: 0.76; 95% CI, 0.57–1.00, p = 0.055). Our retrospective study demonstrated that the concomitant use of RAASi is associated with improved survival outcomes in patients with advanced lung cancer receiving ICIs. These findings suggest a potential therapeutic synergy that warrants further validation in prospective clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsRenin-Angiotensin SystemImmune Checkpoint InhibitorsAngiotensin-Converting Enzyme InhibitorsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedPrognosisDrug SynergismProgression-Free SurvivalAged, 80 and overAdultAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

immune‐checkpoint inhibitorslung cancerrenin‐angiotensin‐aldosterone system inhibitors

Substanzen

Immune Checkpoint InhibitorsAngiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.
  • Department of Internal Medicine, Ankara Bilkent City Hospital, Ankara, Turkey.
  • Department of Medical Oncology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey.

ORCID-Profile: Safa Can Efil, Burak Bilgin, Mehmet Ali Nahit Sendur

Zitieren

APA

Efil, S. C., Ozsan Celebi, S. N., Ozturk, B., Bilgin, B., Hizal, M., Yucel, S., Akinci, M. B., Sener Dede, D., Yalcin, B., & Sendur, M. A. N. (2026). Synergistic prognostic effect of the renin‐angiotensin‐aldosterone system and immune‐checkpoint inhibition in advanced lung cancer: The SPERICIL study. International Journal of Cancer. https://doi.org/10.1002/ijc.70169

Vancouver

Efil SC, Ozsan Celebi SN, Ozturk B, Bilgin B, Hizal M, Yucel S, et al. Synergistic prognostic effect of the renin‐angiotensin‐aldosterone system and immune‐checkpoint inhibition in advanced lung cancer: The SPERICIL study. International Journal of Cancer. 2026. doi:10.1002/ijc.70169

BibTeX
@article{Efil2026,
  author = {Efil, Safa Can and Ozsan Celebi, Sema Nur and Ozturk, Beste and Bilgin, Burak and Hizal, Mutlu and Yucel, Sebnem and Akinci, Muhammed Bulent and Sener Dede, Didem and Yalcin, Bulent and Sendur, Mehmet Ali Nahit},
  title = {Synergistic prognostic effect of the renin‐angiotensin‐aldosterone system and immune‐checkpoint inhibition in advanced lung cancer: The SPERICIL study},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70169}
}
Kostenlos starten →